Europe Genetic Testing Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2022 –2029 |
 حجم السوق (السنة الأساسية) |
USD 4,344.02 Billion |
 حجم السوق (سنة التنبؤ) |
USD 12,730.46 Billion |
 CAGR |
% |
| Major Markets Players |
سوق الاختبارات الجينية في أوروبا، حسب النوع (اختبار الناقل، الاختبار التشخيصي، الاختبار قبل الولادة، فحص حديثي الولادة، الاختبار التنبؤي وما قبل الأعراض، أنواع أخرى)، التكنولوجيا (تسلسل الحمض النووي (الاختبار القائم على NGS)، تفاعل البوليميراز المتسلسل، المصفوفات الدقيقة، تسلسل الجينوم الكامل، التهجين الموضعي الفلوري (FISH)، أخرى)، الأمراض (اضطراب وراثي نادر، السرطان، التليف الكيسي، فقر الدم المنجلي، ضمور العضلات دوشين، الثلاسيميا، مرض هنتنغتون، متلازمة الصبغي X الهش، ضمور العضلات دوشين، أخرى) المستخدم النهائي (المستشفيات والعيادات ومراكز التشخيص والعيادات الخاصة ومقدمي خدمات المختبرات والمختبرات الخاصة) اتجاهات الصناعة والتوقعات حتى عام 2029
تحليل السوق والرؤى
إن سوق الاختبارات الجينية في أوروبا مدفوع بعوامل مثل ارتفاع معدل انتشار الاضطرابات الوراثية ، والتقدم التكنولوجي المتزايد في سوق الاختبارات الجينية الذي يعزز الطلب عليها، فضلاً عن زيادة الاستثمار في البحث والتطوير، مما يؤدي إلى نمو السوق. حاليًا، زادت نفقات الرعاية الصحية في جميع أنحاء البلدان المتقدمة والناشئة، ومن المتوقع أن تخلق ميزة تنافسية للشركات المصنعة لتطوير أسواق اختبارات جينية جديدة ومبتكرة. ومع ذلك، فإن التكلفة العالية المرتبطة بالاختبارات الجينية والأطر التنظيمية الصارمة للاختبارات الجينية.
يقدم تقرير سوق الاختبارات الجينية في أوروبا تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق وتحليل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل، وسيساعدك فريقنا في إنشاء حل لتأثير الإيرادات لتحقيق هدفك المنشود. إن قابلية التوسع وتوسع أعمال وحدات البيع بالتجزئة في البلدان النامية في مختلف المناطق والشراكة مع الموردين للتوزيع الآمن لمنتجات الآلات والأدوية هي المحركات الرئيسية التي دفعت الطلب على السوق في فترة التنبؤ.
تعريف السوق
الاختبار الجيني هو نوع من الاختبارات الطبية التي تحدد التغيرات في الجينات أو الكروموسومات أو البروتينات. يمكن لنتيجة الاختبار الجيني تأكيد أو استبعاد حالة وراثية مشتبه بها أو المساعدة في تحديد فرصة الشخص في الإصابة باضطراب وراثي أو نقله. هناك أكثر من 77000 اختبار جيني قيد الاستخدام حاليًا، ويتم تطوير اختبارات أخرى.
كما أن الابتكارات والتقنيات المتزايدة والعدد المتزايد من اللاعبين في السوق وإطلاق المنتجات الجديدة تعمل أيضًا على دفع نمو سوق الاختبارات الجينية في أوروبا.
Europe genetic testing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 14.6% in the forecast period of 2022 to 2029 and is expected to reach USD 12,730.46 million by 2029 from USD 4,344.02 million in 2021.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Type (Carrier Testing, Diagnostic Testing, Prenatal Testing, New Born Screening, Predictive And Presymptomatic Testing, Other Types), Technology (DNA Sequencing (NGS-Based Testing), Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, Duchenne Muscular Dystrophy, Others) End User (Hospitals, Clinics, Diagnostic Centres, Private Clinics, Laboratory Service Providers, Private Laboratories) |
|
Countries Covered |
Germany, France, U.K. Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest Of Europe |
|
Market Players Covered |
Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Illumina, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., Abbott, Eurofins Scientific, Biocartis, Cepheid ( A subsidiary of Danaher), PacBio, BioReference, Natera, Inc. among others |
Europe Genetic Testing Market Dynamics
Drivers
- Growing prevalence of genetic disorders
For instance,
- As per the publication of January 2019, entitled “European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer”, this has been indicated that BRCA1/2 tests are widely spread across U.K. and other European regions indicated for cancer testing.
- Organized genetic testing programs are provided in European Union which ensures that high-quality screening services are provided to population.
Therefore, this is raising the demand for genetic testing market.
- Increase In The Adoption Of Next Generation Sequencing
As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight into the molecular underpinnings of individual tumors and specific receptors.
NGS offers advantages in accuracy, sensitivity, and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.
For instance,
- NGS has been also explored for comprehensive profiling of pharmacogenetics with relevance to drug Pharmacokinetics and Pharmacodynamics, initial reports of 2017 suggest that this technology may represent a reliable and efficient tool to discover both common and rare genetic variations in these genes.
Thus, this is expected to act as a driver for the growth of the genetic testing market.
Opportunities
-
Increasing Research And Development
For instance,
-
As per the publication of 2020, entitled “Availability and funding of clinical genomic sequencing globally”, this has been indicated that maximally many European countries other than United Kingdom have increasing availability of genetic tests for promoting the growth of NGS (next generation sequencing) and genomic medicine.
-
Rising Disposable Income
The expense of money used by a country on its healthcare and its growth rate over time is inclined by a wide variety of economic and social factors including the financing arrangements and structure of the organization of the health system. In particular, there is a strong association between the complete income level of a country and how much the population of that country spends on health care.
Also, the strategic initiatives taken by key market players will provide structural integrity and future opportunities for the genetic testing market in the forecast period of 2022-2029.
Restraints/Challenges
- High Cost Of Genetic Testing
Genetic testing can be expensive and may not be covered by some health insurance plans. The numerous genetic tests differ in costs as per the targeted disease for which it is tested.
According to Breastcancer.org, the cost of genetic testing for cancer can vary greatly and can be between $300 and $5,000. How much genetic testing costs can depend on the type of test as well as how complex it is
Genetic testing can cost anywhere from $100 to more than $2,000, depending on the test's nature and complexity. If more than one test is required or numerous family members must be tested to acquire a significant result, the expense rises. The cost of neonatal screening varies by state.
Covid-19 Impact on the Europe Genetic Testing Market
The COVID-19 has positively affected the market as many genetic and serological tests were conducted for COVID-19 which raises the demand for genetic testing during this period.
Recent Development
- In December 2021, Thermo Fisher Scientific Inc., announced that it has completed its acquisition of PPD, Inc., a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. This acquisition helped to generate more revenue and boosted the market growth.
Europe Genetic Testing Market Scope
يتم تقسيم سوق الاختبارات الجينية في أوروبا إلى نوع وتقنية وأمراض ومستخدم نهائي. سيساعدك النمو بين هذه القطاعات على تحليل قطاعات النمو الضئيلة في الصناعات وتزويد المستخدمين بنظرة عامة قيمة على السوق ورؤى السوق لاتخاذ قرارات استراتيجية لتحديد تطبيقات السوق الأساسية.
يكتب
- الاختبارات التشخيصية
- اختبارات ما قبل الولادة
- فحص حديثي الولادة
- الاختبارات التنبؤية والاختبارات ما قبل الأعراض
- اختبار الناقل
- أنواع أخرى
على أساس النوع، يتم تقسيم سوق الاختبارات الجينية في أوروبا إلى اختبارات تشخيصية، واختبارات ما قبل الولادة، وفحص حديثي الولادة، واختبارات تنبؤية واختبارات ما قبل الأعراض، واختبارات الناقل وأنواع أخرى.
تكنولوجيا
- تفاعل البوليميراز المتسلسل
- تسلسل الحمض النووي (اختبار يعتمد على NGS)
- تسلسل الجينوم الكامل
- المصفوفات الدقيقة
- التهجين الموضعي الفلوري (FISH)
- آحرون
على أساس التكنولوجيا، يتم تقسيم سوق الاختبارات الجينية في أوروبا إلى تسلسل الحمض النووي (الاختبار القائم على NGS)، وتفاعل البوليميراز المتسلسل، والمصفوفات الدقيقة، وتسلسل الجينوم الكامل، والتهجين الموضعي الفلوري (FISH)، وغيرها.
الأمراض
- سرطان
- فقر الدم المنجلي
- الثلاسيميا
- اضطراب وراثي نادر
- متلازمة إكس الهش
- ضمور العضلات دوشين
- مرض هنتنغتون
- تليّف كيسي
- آحرون
على أساس الأمراض، يتم تقسيم سوق الاختبارات الجينية في أوروبا إلى اضطراب وراثي نادر، والسرطان، والتليف الكيسي، وفقر الدم المنجلي، وخلل العضلات دوشين، والثلاسيميا، ومرض هنتنغتون، ومتلازمة الصبغي X الهش، وغيرها.
المستخدم النهائي
- المستشفيات
- العيادات
- مراكز التشخيص
- العيادات الخاصة
- مقدمي خدمات المختبر
- المختبرات الخاصة
على أساس المستخدمين النهائيين، يتم تقسيم سوق الاختبارات الجينية في أوروبا إلى المستشفيات والعيادات ومراكز التشخيص والعيادات الخاصة ومقدمي الخدمات المعملية والمختبرات الخاصة.
تحليل/رؤى إقليمية لسوق الاختبارات الجينية
يتم تحليل سوق الاختبارات الجينية وتوفير رؤى حول حجم السوق والاتجاهات حسب البلد والنوع والتكنولوجيا والأمراض والمستخدم النهائي كما هو مذكور أعلاه.
تعد ألمانيا من الدول المهيمنة الرئيسية في السوق بسبب الانتشار المتزايد للاضطرابات الوراثية بين السكان في هذه البلدان. وهي تهيمن على سوق الاختبارات الجينية من حيث حصة السوق وإيرادات السوق وستستمر في ازدهار هيمنتها خلال فترة التوقعات. ويرجع هذا إلى العيوب الوراثية والانحرافات الكروموسومية لدى السكان في المناطق، كما أن التطور السريع في مجال البحث يعزز السوق.
كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في اللوائح في السوق والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات، مثل المبيعات الجديدة والاستبدالية، والتركيبة السكانية للدولة، وعلم الأوبئة المرضية، ورسوم الاستيراد والتصدير، من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. بالإضافة إلى ذلك، يتم النظر في وجود وتوافر العلامات التجارية العالمية والتحديات التي تواجهها بسبب المنافسة الشديدة من العلامات التجارية المحلية والمحلية، وتأثير قنوات المبيعات أثناء تقديم تحليل توقعات لبيانات الدولة.
تحليل المشهد التنافسي وحصة سوق الاختبارات الجينية
يوفر المشهد التنافسي لسوق الاختبارات الجينية تفاصيل حول المنافسين. وتشمل التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. وتتعلق نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق الاختبارات الجينية.
بعض اللاعبين الرئيسيين العاملين في سوق الاختبارات الجينية هم Thermo Fisher Scientific Inc. و Illumina, Inc. و QIAGEN و F. Hoffmann-La Roche Ltd. و Myriad Genetics, Inc. و Abbott و Eurofins Scientific و Biocartis و Cepheid (شركة تابعة لـ Danaher) و PacBio و BioReference و Natera, Inc. وغيرها
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. يتم تحليل بيانات السوق وتقديرها باستخدام إحصاءات السوق والنماذج المتماسكة. بالإضافة إلى ذلك، يعد تحليل حصة السوق وتحليل الاتجاهات الرئيسية من عوامل النجاح الرئيسية في تقرير السوق. منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تنطوي على استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأساسي (خبير الصناعة). وبصرف النظر عن هذا، تتضمن نماذج البيانات شبكة وضع البائعين وتحليل الخط الزمني للسوق ونظرة عامة على السوق والدليل وشبكة وضع الشركة وتحليل حصة الشركة في السوق ومعايير القياس والتحليل العالمي مقابل الإقليمي وتحليل حصة البائعين. يرجى طلب مكالمة محلل في حالة وجود استفسار آخر.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE GENETIC TESTING MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 STRATEGIC INITIATIVES:
4.4 CONCLUSION:
4.5 INDUSTRY INSIGHTS
4.5.1 CANCER GENETICS RISK ASSESSMENT AND COUNSELING
4.5.2 GENETIC TESTS PRICING
4.5.3 KEY INSIGHTS
5 EPIDERMIOLOGY
6 EUROPE GENETIC TESTING MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF GENETIC DISORDERS
7.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
7.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER
7.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
7.2 RESTRAINTS
7.2.1 HIGH COST OF GENETIC TESTING
7.2.2 CYBER SECURITY CONCERNS IN GENOMICS
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
7.3.2 TECHNOLOGICAL ADVANCEMENT
7.3.3 INCREASING RESEARCH AND DEVELOPMENT
7.3.4 RISING DISPOSABLE INCOME
7.4 CHALLENGES
7.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING
7.4.2 STRINGENT REGULATION POLICY
8 EUROPE GENETIC TESTING MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC TESTING
8.3 PRENATAL TESTING
8.3.1 NON-INVASIVE SCREENING
8.3.1.1 BY SCREENING METHOD
8.3.1.1.1 WHOLE GENOME SEQUENCING
8.3.1.1.2 COUNTING OF CFDNA FRAGMENTS
8.3.1.1.3 OTHERS
8.3.1.2 BY CONDITION
8.3.1.2.1 TRISOMY 21
8.3.1.2.2 KLINEFELTER SYNDROME
8.3.1.2.3 JACOBS SYNDROME
8.3.1.2.4 CYSTIC FIBROSIS
8.3.1.2.5 TURNER SYNDROME
8.3.1.2.6 TRISOMY 18
8.3.1.2.7 HEMOPHILIA
8.3.1.2.8 TRISOMY 13
8.3.1.2.9 MICRODELETION SYNDROME
8.3.1.2.10 FETAL GENDER
8.3.1.2.11 OTHERS
8.3.1.3 BY SCREENING TYPE
8.3.1.3.1 CARRIER SEQUENCING
8.3.1.3.2 SEQUENTIAL SEQUENCING
8.3.2 MATERNAL SERUM QUAD SCREENING
8.4 NEW BORN SCREENING
8.4.1.1 SICKLE CELL DISEASE
8.4.1.2 CONGENITAL HYPOTHYROIDISM
8.4.1.3 PHENYLKETONURIA (PKU)
8.4.1.4 GALACTOSEMIA
8.4.1.5 MAPLE SYRUP URINE DISEASE
8.4.1.6 OTHERS
8.5 PREDICTIVE AND PRESYMPTOMATIC TESTING
8.6 CARRIER TESTING
8.6.1 BY TEST TYPE
8.6.1.1 MOLECULAR SCREENING TEST
8.6.1.2 BIOCHEMICAL SCREENING TEST
8.6.2 BY TYPE
8.6.2.1 EXPANDED CARRIER SCREENING
8.6.2.1.1 PREDESIGNED PANEL TESTING
8.6.2.1.2 CUSTOM-MADE PANEL TESTING
8.6.2.2 TARGETED DISEASE CARRIER SCREENING
8.6.2.2.1 BY MEDICAL CONDITION
8.6.2.2.2 HEMATOLOGICAL CONDITIONS
8.6.2.2.3 PULMONARY CONDITIONS
8.6.2.2.4 NEUROLOGICAL CONDITIONS
8.6.2.2.5 OTHER CONDITIONS
8.7 OTHER TYPES
9 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 POLYMERASE CHAIN REACTION
9.2.1 REAL-TIME PCR (QPCR)
9.2.2 DIGITAL PCR (DPCR)
9.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR)
9.2.4 HOT-START PCR
9.2.5 MULTIPLEX PCR
9.2.6 OTHER PCR
9.3 DNA SEQUENCING (NGS-BASED TESTING)
9.3.1 NEXT GENERATION SEQUENCING (NGS)
9.3.2 SANGER SEQUENCING (SINGLE GENE)
9.3.3 OTHER
9.4 WHOLE GENOME SEQUENCING
9.5 MICROARRAYS
9.5.1 DNA MICROARRAYS
9.5.2 PROTEIN MICROARRAYS
9.5.3 OTHER MICROARRAYS
9.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH)
9.7 OTHERS
10 EUROPE GENETIC TESTING MARKET, BY DISEASES
10.1 OVERVIEW
10.2 CANCER
10.2.1 BREAST
10.2.2 COLON
10.2.3 LUNG
10.2.4 PROSTATE
10.2.5 OTHERS
10.3 SICKLE CELL ANEMIA
10.4 THALASSEMIA
10.5 RARE GENETIC DISORDER
10.5.1 TRISOMY 21
10.5.2 MONOSOMY X
10.5.3 TRISOMY 13
10.5.4 MICRODELETION SYNDROME
10.5.5 TRISOMY 18
10.5.6 OTHERS
10.6 FRAGILE X SYNDROME
10.7 DUCHENNE MUSCULAR DYSTROPHY
10.8 HUNTINGTON'S DISEASE
10.9 CYSTIC FIBROSIS
10.1 OTHERS
11 EUROPE GENETIC TESTING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 DIAGNOSTIC CENTERS
11.5 PRIVATE CLINICS
11.6 LABORATORY SERVICE PROVIDERS
11.7 PRIVATE LABORATORIES
12 EUROPE GENETIC TESTING MARKET, BY REGION
12.1 EUROPE
12.1.1 GERMANY
12.1.2 FRANCE
12.1.3 U.K.
12.1.4 RUSSIA
12.1.5 ITALY
12.1.6 SPAIN
12.1.7 TURKEY
12.1.8 NETHERLANDS
12.1.9 SWITZERLAND
12.1.10 BELGIUM
12.1.11 REST OF EUROPE
13 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: EUROPE
14 WOT ANALYSIS
15 COMPANY PROFILE
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.1.4.1 ACQUISITION
15.1.4.2 COLLABORATION
15.2 CEPHEID
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 BUSINEES EXPANSION
15.3 FULGENT GENETICS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.3.5.1 ACQUISITION
15.4 PERKINELMER INC.
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.4.5.1 PRODUCT LAUNCH
15.5 THERMO FISHER SCIENTIFIC INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.5.5.1 COLLABORATION
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIOCARTIS
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.7.4.1 PARTNERSHIP
15.7.4.2 AGREEMENT
15.8 BIO-HELIX
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIO-RAD LABORATORIES, INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.9.4.1 ACQUISITION
15.9.4.2 PARTNERSHIP
15.1 BIOREFERENCE
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.10.4.1 ACQUISITION
15.11 ELITECHGROUP
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.11.3.1 PRODUCT LAUNCH
15.11.3.2 BUSINESS EXPANSION
15.12 EUROFINS SCIENTIFIC
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.12.4.1 PRODUCT LAUNCH
15.13 EUGENE LABS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 F. HOFFMANN-LA ROCHE LTD)
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS (PARENT COMPANY)
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.14.4.1 PRODUCT LAUNCH
15.15 GENES2ME
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 INVITAE CORPORATION
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 MAPMYGENOME
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 MEDGENOME
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 MYRIAD GENETICS
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.2 NATERA, INC.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 PARTNERSHIP
15.21 OTOGENRTICS
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.22 PACBIO
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PORTFOLIO
15.22.4 RECENT DEVELOPMENT
15.23 QIAGEN
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 PARTNERSHIP
15.23.3.2 PRODUCT LAUNCH
15.24 SEMA4 OPCO, INC.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 SORENSON GENOMICS
15.25.1 COMPANY SNAPSHOT
15.25.2 PRODUCT PORTFOLIO
15.25.3 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 3 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 4 EUROPE DIAGNOSTIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 8 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 9 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 11 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 12 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 14 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 15 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 16 EUROPE NEW BORN SCREENING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 EUROPE PREDICTIVE AND PRESYMPTOMATIC TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 21 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 22 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 23 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 24 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 25 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 26 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 28 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 29 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE OTHER TYPES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 32 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE DNA SEQUENCING (NGS-BASED TESTING) IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 36 EUROPE WHOLE GENOME SEQUENCING IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 39 EUROPE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 42 EUROPE CANCER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 44 EUROPE SICKLE CELL ANEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE THALASSEMIA IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 47 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 48 EUROPE FRAGILE X SYNDROME IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 49 EUROPE DUCHENNE MUSCULAR DYSTROPHY IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 50 EUROPE HUNTINGTON'S DISEASE IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 51 EUROPE CYSTIC FIBROSIS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 52 EUROPE OTHERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 53 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE HOSPITALS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 56 EUROPE DIAGNOSTIC CENTERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE PRIVATE CLINICS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE LABORATORY SERVICE PROVIDERS IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE PRIVATE LABORATORIES IN GENETIC TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 60 EUROPE GENETIC TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 61 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 63 EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 64 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 EUROPE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 67 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 68 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 69 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 70 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 71 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 72 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 73 EUROPE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 74 EUROPE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 76 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 77 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 78 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 80 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 81 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 83 EUROPE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 84 EUROPE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 85 EUROPE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 86 EUROPE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 87 EUROPE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 88 EUROPE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 89 EUROPE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 90 EUROPE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 91 EUROPE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 92 EUROPE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 GERMANY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 96 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 98 GERMANY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 99 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 100 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 101 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 102 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 103 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 105 GERMANY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 106 GERMANY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 108 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 109 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 110 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 112 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 113 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 115 GERMANY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 116 GERMANY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 117 GERMANY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 118 GERMANY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 119 GERMANY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 120 GERMANY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 121 GERMANY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 122 GERMANY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 123 GERMANY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 124 GERMANY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 125 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 127 FRANCE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 128 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 130 FRANCE PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 131 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 132 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 133 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 134 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 135 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 136 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 137 FRANCE NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 138 FRANCE NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 140 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 141 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 142 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 144 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 145 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 147 FRANCE EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 148 FRANCE CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 149 FRANCE GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 150 FRANCE POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 151 FRANCE DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 152 FRANCE MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 153 FRANCE GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 154 FRANCE RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 155 FRANCE CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 156 FRANCE GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 159 U.K. GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 160 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 162 U.K. PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 163 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 164 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 165 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 166 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 167 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 168 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 169 U.K. NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 170 U.K. NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 172 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 173 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 174 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 176 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 177 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 179 U.K. EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 180 U.K. CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 181 U.K. GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 182 U.K. POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 183 U.K. DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 184 U.K. MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 185 U.K. GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 186 U.K. RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 187 U.K. CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 188 U.K. GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 189 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 191 RUSSIA GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 192 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 194 RUSSIA PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 195 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 196 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 197 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 198 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 199 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 200 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 201 RUSSIA NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 202 RUSSIA NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 204 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 205 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 206 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 208 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 209 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 211 RUSSIA EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 212 RUSSIA CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 213 RUSSIA GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 214 RUSSIA POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 215 RUSSIA DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 216 RUSSIA MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 217 RUSSIA GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 218 RUSSIA RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 219 RUSSIA CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 220 RUSSIA GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 221 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 223 ITALY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 224 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 226 ITALY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 227 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 228 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 229 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 230 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 231 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 232 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 233 ITALY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 234 ITALY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 236 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 237 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 238 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 239 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 240 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 241 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 243 ITALY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 244 ITALY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 245 ITALY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 246 ITALY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 247 ITALY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 248 ITALY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 249 ITALY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 250 ITALY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 251 ITALY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 252 ITALY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 253 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 254 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 255 SPAIN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 256 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 258 SPAIN PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 259 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 260 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 261 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 262 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 263 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 264 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 265 SPAIN NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 266 SPAIN NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 267 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 268 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 269 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 270 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 272 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 273 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 275 SPAIN EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 276 SPAIN CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 277 SPAIN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 278 SPAIN POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 279 SPAIN DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 280 SPAIN MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 281 SPAIN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 282 SPAIN RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 283 SPAIN CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 284 SPAIN GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 285 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 287 TURKEY GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 288 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 290 TURKEY PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 291 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 292 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 293 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 294 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 295 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 296 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 297 TURKEY NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 298 TURKEY NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 300 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 301 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 302 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 303 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 304 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 305 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 307 TURKEY EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 308 TURKEY CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 309 TURKEY GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 310 TURKEY POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 311 TURKEY DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 312 TURKEY MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 313 TURKEY GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 314 TURKEY RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 315 TURKEY CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 316 TURKEY GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 317 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 319 NETHERLANDS GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 320 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 322 NETHERLANDS PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 323 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 324 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 325 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 326 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 327 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 328 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 329 NETHERLANDS NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 330 NETHERLANDS NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 332 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 333 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 334 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 336 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 337 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 338 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 339 NETHERLANDS EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 340 NETHERLANDS CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 341 NETHERLANDS GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 342 NETHERLANDS POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 343 NETHERLANDS DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 344 NETHERLANDS MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 345 NETHERLANDS GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 346 NETHERLANDS RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 347 NETHERLANDS CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 348 NETHERLANDS GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 349 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 350 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 351 SWITZERLAND GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 352 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 353 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 354 SWITZERLAND PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 355 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 356 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 357 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 358 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 359 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 360 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 361 SWITZERLAND NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 362 SWITZERLAND NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 364 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 365 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 366 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 367 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 368 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 369 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 371 SWITZERLAND EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 372 SWITZERLAND CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 373 SWITZERLAND GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 374 SWITZERLAND POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 375 SWITZERLAND DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 376 SWITZERLAND MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 377 SWITZERLAND GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 378 SWITZERLAND RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 379 SWITZERLAND CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 381 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 382 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 383 BELGIUM GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 384 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 386 BELGIUM PRENATAL TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 387 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (USD MILLION)
TABLE 388 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (UNITS)
TABLE 389 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING METHOD, 2020-2029 (ASP)
TABLE 390 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY CONDITION, 2020-2029 (USD MILLION)
TABLE 391 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (USD MILLION)
TABLE 392 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (UNITS)
TABLE 393 BELGIUM NON-INVASIVE SCREENING IN GENETIC TESTING MARKET, BY SCREENING TYPE, 2020-2029 (ASP)
TABLE 394 BELGIUM NEW-BORN SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 395 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)
TABLE 396 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)
TABLE 397 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TEST TYPE, 2020-2029 (ASP)
TABLE 398 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 400 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 401 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 402 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 403 BELGIUM EXPANDED CARRIER SCREENING IN GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 404 BELGIUM CARRIER TESTING IN GENETIC TESTING MARKET, BY MEDICAL CONDITION, 2020-2029 (USD MILLION)
TABLE 405 BELGIUM GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 406 BELGIUM POLYMERASE CHAIN REACTION IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 407 BELGIUM DNA SEQUENCING IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 408 BELGIUM MICROARRAYS IN GENETIC TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 409 BELGIUM GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 410 BELGIUM RARE GENETIC DISORDER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 411 BELGIUM CANCER IN GENETIC TESTING MARKET, BY DISEASES, 2020-2029 (USD MILLION)
TABLE 412 BELGIUM GENETIC TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 413 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 414 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 415 REST OF EUROPE GENETIC TESTING MARKET, BY TYPE, 2020-2029 (ASP)
List of Figure
FIGURE 1 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 2 EUROPE GENETIC TESTING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE GENETIC TESTING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE GENETIC TESTING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE GENETIC TESTING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE GENETIC TESTING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE GENETIC TESTING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE GENETIC TESTING MARKET: APPLICATION COVERAGE GRID
FIGURE 9 EUROPE GENETIC TESTING MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE GENETIC TESTING MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE EUROPE GENETIC TESTING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 DIAGNOSTIC TESTING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE GENETIC TESTING MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE GENETIC TESTING MARKET AND ASIA-PACIFIC EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE GENETIC TESTING MARKET
FIGURE 15 EUROPE GENETIC TESTING MARKET: BY TYPE, 2021
FIGURE 16 EUROPE GENETIC TESTING MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 17 EUROPE GENETIC TESTING MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 18 EUROPE GENETIC TESTING MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2021
FIGURE 20 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, 2022-2029 (USD MILLION)
FIGURE 21 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 22 EUROPE GENETIC TESTING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 23 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2021
FIGURE 24 EUROPE GENETIC TESTING MARKET: BY DISEASES, 2022-2029 (USD MILLION)
FIGURE 25 EUROPE GENETIC TESTING MARKET: BY DISEASES, CAGR (2022-2029)
FIGURE 26 EUROPE GENETIC TESTING MARKET: BY DISEASES, LIFELINE CURVE
FIGURE 27 EUROPE GENETIC TESTING MARKET: BY END USER, 2021
FIGURE 28 EUROPE GENETIC TESTING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 EUROPE GENETIC TESTING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 EUROPE GENETIC TESTING MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 EUROPE GENETIC TESTING MARKET: SNAPSHOT (2021)
FIGURE 32 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021)
FIGURE 33 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 34 EUROPE GENETIC TESTING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 35 EUROPE GENETIC TESTING MARKET: BY TYPE (2022-2029)
FIGURE 36 EUROPE GENETIC TESTING MARKET: COMPANY SHARE 2021 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
